The Stack

Sold by case = 10 vials for each product. 30 vials total.

Components: Retatrutide + GLOW (BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg) + NAD⁺
For Research Use Only. Not for Human or Veterinary Consumption.

This advanced research stack features Retatrutide—a multi-receptor agonist under investigation—combined with the GLOW peptide blend (BPC-157, TB-500, GHK-Cu) and NAD+, a key metabolic coenzyme. Designed for scientific study into complex cellular environments, this combination supports exploration of molecular pathways related to signaling peptides, mitochondrial redox states, and extracellular matrix interactions. This formulation is suitable for in vitro or in vivo model systems evaluating synergistic biochemical processes.

All materials are for qualified laboratory research only. Not intended for medical, diagnostic, or therapeutic use in humans or animals.

Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors shown in Phase 2 clinical trials (SURMOUNT-3) to produce up to 24.2% total body weight loss over 48 weeks. Its mechanisms include delayed gastric emptying, appetite suppression, and enhanced energy expenditure.

GLOW combines 

• BPC-157, a gastric-derived peptide that accelerates angiogenesis, reduces inflammation, and speeds soft tissue and joint healing;
• TB-500 (Thymosin Beta-4 fragment), which promotes cell migration and muscle recovery through actin regulation;
• GHK-Cu, a copper peptide shown to increase collagen synthesis, improve skin elasticity, and reverse visible signs of aging in multiple dermatological studies.

NAD+ is essential for mitochondrial function and DNA repair. NAD+ supplementation supports improved metabolic function, insulin sensitivity, and age-related cellular rejuvenation, with promising results in early-stage human trials for anti-aging and neuroprotection.